Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Denitsa Panayotova

Medical University of Sofia, Bulgaria

Title: Suspected side effects in geriatric patients following vaccination with the vaccines indicated for SARS-CоV-2 on the territory of the EU-The role of the clinical pharmacist

Biography

Biography: Denitsa Panayotova

Abstract

Statement of the problem: Over the last years, the European regulator has incorporated all available mechanisms and also created new regulatory approaches with pharmacovigilance focus to provide European citizens with quality, safe and effective vaccines. The aim of this study was to analyze the Suspected Side Effects (SSI) in geriatric patients following vaccination with COVID-19 vaccines and the possibilities for their prevention through the inclusion of clinical pharmacists in the vaccination process.

Methodology & theoretical orientation: Scoping literature review was conducted on the information concerning safety of vaccines in the scientific databases using keywords search (COVID-19 vaccines, Pharmacovigilance, Safety of COVID-19 vaccines). A critical analysis was performed on the information in EudraVigilance System (EVS) for the vaccines indicated for SARS-CоV-2 on the territory of the EU. The analysis included the period from first marketing authorization for vaccine with indication SARS-CoV-2 infection and ended approximately two years later.

Findings: From 21st December to 14th May 2022, the reported cases in the EVS for geriatric patients were 272 253 (26,8% of all reported cases), of which 61% affect women and respectively 38% men. The clinical pharmacist has a crucial role in discussing with geriatric patients any vaccine concerns emphasizing on the most prevalent side effects, importance of vaccination, managing drug-related problems and contraindications. Adding the peculiarities of elderly patients, exclusion from most clinical trials and the relatively lower rates of reporting for this age group, the clinical pharmacist should proactively monitor the course of vaccination, participate and encourage reporting of any relevant safety information.

Conclusion: Considering the age-related changes in pharmacokinetics and pharmacodynamics and the increased risk of side effects among geriatrics, more attention should be paid to this vulnerable group and the clinical pharmacist’s potential to provide them with quality pharmaceutical care, corresponding to the constant changing COVID-19 situation.